Picture of Zealand Pharma A/S logo

ZEAL Zealand Pharma A/S Share Price

0.000.00%
dk flag iconLast trade - 00:00
HealthcareSpeculativeLarge CapMomentum Trap

Momentum

Relative Strength (%)
1m+51.27%
3m+81.21%
6m+104.8%
1yr+173.9%
Volume Change (%)
10d/3m+3.93%
Price vs... (%)
52w High-4.01%
50d MA+29.26%
200d MA+100.45%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)n/a
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value28.1
Price to Tang. Book28.31
Price to Free Cashflown/a
Price to Sales130.55
EV to EBITDAn/a

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-41.75%
Return on Equity-58.43%
Operating Margin-206.49%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Zealand Pharma A/S EPS forecast chart

Profile Summary

Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
April 1st, 1997
Public Since
November 1st, 2010
No. of Shareholders
36,798
No. of Employees
253
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
dk flag iconOMX Nordic Exchange - Copenhagen
Shares in Issue
62,242,069
Blurred out image of a map
Address
Sydmarken 11, SOEBORG, 2860
Web
https://www.zealandpharma.com/
Phone
+45 null88773600
Contact
Anna Krassowska
Auditors
Ernst & Young Godkendt Revisionspartnerselskab

ZEAL Share Price Performance

Latest News for ZEAL

Upcoming Events for ZEAL

Q1 2024 Zealand Pharma A/S Earnings Release

Half Year 2024 Zealand Pharma A/S Earnings Release

Similar to ZEAL

Picture of ChemoMetec A/S logo

ChemoMetec A/S

dk flag iconOMX Nordic Exchange - Copenhagen

Picture of Genmab A/S logo

Genmab A/S

dk flag iconOMX Nordic Exchange - Copenhagen

Picture of Gubra A/S logo

Gubra A/S

dk flag iconOMX Nordic Exchange - Copenhagen

Picture of Orphazyme A/S logo

Orphazyme A/S

dk flag iconOMX Nordic Exchange - Copenhagen

Picture of ViroGates A/S logo

ViroGates A/S

dk flag iconOMX Nordic Exchange - Copenhagen

FAQ